Brotizolam

	WikiDoc Resources for Brotizolam
Articles
Most recent articles on Brotizolam Most cited articles on Brotizolam Review articles on Brotizolam Articles on Brotizolam in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Brotizolam Images of Brotizolam Photos of Brotizolam Podcasts & MP3s on Brotizolam Videos on Brotizolam
Evidence Based Medicine
Cochrane Collaboration on Brotizolam Bandolier on Brotizolam TRIP on Brotizolam
Clinical Trials
Ongoing Trials on Brotizolam at Clinical Trials.gov Trial results on Brotizolam Clinical Trials on Brotizolam at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Brotizolam NICE Guidance on Brotizolam NHS PRODIGY Guidance FDA on Brotizolam CDC on Brotizolam
Books
Books on Brotizolam
News
Brotizolam in the news Be alerted to news on Brotizolam News trends on Brotizolam
Commentary
Blogs on Brotizolam
Definitions
Definitions of Brotizolam
Patient Resources / Community
Patient resources on Brotizolam Discussion groups on Brotizolam Patient Handouts on Brotizolam Directions to Hospitals Treating Brotizolam Risk calculators and risk factors for Brotizolam
Healthcare Provider Resources
Symptoms of Brotizolam Causes & Risk Factors for Brotizolam Diagnostic studies for Brotizolam Treatment of Brotizolam
Continuing Medical Education (CME)
CME Programs on Brotizolam
International
Brotizolam en Espanol Brotizolam en Francais
Business
Brotizolam in the Marketplace Patents on Brotizolam
Experimental / Informatics
List of terms related to Brotizolam

Brotizolam
Clinical data
Pregnancy; category	?;
Routes of; administration	Oral
ATC code	N05CD09 (WHO) ;
Legal status
Legal status	US: Schedule IV ;
Pharmacokinetic data
Bioavailability	48-95%
Metabolism	Hepatic
Elimination half-life	4.4 hours (range, 2.6–6.9 h)
Excretion	Renal
Identifiers
	IUPAC name 2-Bromo-4-(2-chlorphenyl)-9-methyl-6H- thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)benzodiazepine;
CAS Number	57801-81-7;
PubChem CID	2451;
DrugBank	?;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C15H10BrClN4S
Molar mass	393.7 g/mol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Brotizolam (marketed under brand name Lendormin) is a drug which is thienobenzodiazepine (a benzodiazepine derivative). It possesses anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant properties, and is considered to be similar in effect to short-acting benzodiazepines such as triazolam. It is used in the short term treatment of insomnia although due to its short half life it is considered to have relatively high abuse potential and so would not be a first-line treatment. Brotizolam is a potent drug with a dosage of between 0.5 and 1.5 milligrams, but is rapidly eliminated with an average half life of 4.4 hours (range 3.6 - 7.9 hours).

Brotizolam is not approved for sale in the UK, United States or Canada.

Pharmacology

Brotizolam induces impairment of motor function and has hypnotic properties.^[1] Brotizolam increases the slow wave light sleep (SWLS) in a dose-dependent manner whilst suppressing deep sleep stages. Less time is spent in stages 3 and 4 which are the deep sleep stages when benzodiazepines such as brotizolam are used. Benzodiazepines are therefore not good hypnotics in the treatment of insomnia. The suppression of deep sleep stages by benzodiazepines may be especially problematic to the elderly as they naturally spend less time in the deep sleep stage.^[2]

Indications

Insomnia. Brotizolam is prescribed for the short term treatment, 2 - 4 weeks only of severe insomnia. Insomnia can be described as a difficulty falling asleep, frequent awakening, early awakenings or a combination of each. Brotizolam is a short-intermediate acting benzodiazepine and is sometimes used in patients who have difficulty in maintaining sleep or getting to sleep. Hypnotics should only be used on a short term basis or in those with chronic insomnia on an occasional basis.^[3]

Notes

↑ Yasui M (2005). "[Pharmacological profiles of benzodiazepinergic hypnotics and correlations with receptor subtypes]". 25 (3): 143–51. PMID 16045197. Text "Nihon Shinkei Seishin Yakurigaku Zasshi. " ignored (help); Unknown parameter |coauthors= ignored (help); Unknown parameter |month= ignored (help)
↑ Noguchi H (2004). "Electroencephalographic properties of zaleplon, a non-benzodiazepine sedative/hypnotic, in rats" (pdf). J Pharmacol Sci. 94 (3): 246–51. PMID 15037809. Unknown parameter |coauthors= ignored (help); Unknown parameter |month= ignored (help)
↑ Rickels K. (1986). "The clinical use of hypnotics: indications for use and the need for a variety of hypnotics". Acta Psychiatr Scand Suppl. 332: 132–41. PMID 2883820.

References

{{Reflist|2]]

Greenblatt DJ, Locniskar A, Shader RI. Pilot pharmacokinetic study of brotizolam, a thienodiazepine hypnotic, using electron-capture gas-liquid chromatography. Sleep. 1983;6(1):72-6. PMID 6844800.

Langley MS, Clissold SP. Brotizolam. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy as an hypnotic. Drugs. 1988 Feb;35(2):104-22.

Bechtel WD. Pharmacokinetics and metabolism of brotizolam in humans. British Journal of Clinical Pharmacology. 1983;16 Suppl 2:279S-283S.

Jochemsen R. Pharmacokinetics of brotizolam in healthy subjects following intravenous and oral administration. British Journal of Clinical Pharmacology. 1983;16 Suppl 2:285S-290S.

External links

Inchem.org - Brotizolam

Template:Benzodiazepines

Template:Pharma-stub sv:Brotizolam

[1] Yasui M (2005). "[Pharmacological profiles of benzodiazepinergic hypnotics and correlations with receptor subtypes]". 25 (3): 143–51. PMID 16045197. Text "Nihon Shinkei Seishin Yakurigaku Zasshi. " ignored (help); Unknown parameter |coauthors= ignored (help); Unknown parameter |month= ignored (help)

[2] Noguchi H (2004). "Electroencephalographic properties of zaleplon, a non-benzodiazepine sedative/hypnotic, in rats" (pdf). J Pharmacol Sci. 94 (3): 246–51. PMID 15037809. Unknown parameter |coauthors= ignored (help); Unknown parameter |month= ignored (help)

[3] Rickels K. (1986). "The clinical use of hypnotics: indications for use and the need for a variety of hypnotics". Acta Psychiatr Scand Suppl. 332: 132–41. PMID 2883820.

[1]

[2]

[3]